Insider Selling: Phreesia (NYSE:PHR) Insider Sells 6,038 Shares of Stock

Phreesia, Inc. (NYSE:PHR) insider David Linetsky sold 6,038 shares of the firm’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $16.36, for a total value of $98,781.68. Following the completion of the sale, the insider directly owned 223,942 shares of the company’s stock, valued at approximately $3,663,691.12. The trade was a 2.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

David Linetsky also recently made the following trade(s):

• On Thursday, January 15th, David Linetsky sold 1,743 shares of Phreesia stock. The stock was sold at an average price of $16.38, for a total value of $28,550.34.
• On Thursday, January 8th, David Linetsky sold 6,106 shares of Phreesia stock. The shares were sold at an average price of $17.01, for a total value of $103,863.06.
• On Wednesday, December 17th, David Linetsky sold 94 shares of Phreesia stock. The stock was sold at an average price of $16.49, for a total transaction of $1,550.06.

Phreesia Stock Performance

Shares of NYSE:PHR traded down $0.63 on Tuesday, hitting $15.76. The company had a trading volume of 888,246 shares, compared to its average volume of 1,011,187. The stock has a market cap of $950.23 million, a price-to-earnings ratio of -157.59 and a beta of 0.61. The stock has a 50 day moving average price of $18.24 and a 200 day moving average price of $23.18. Phreesia, Inc. has a 1-year low of $15.41 and a 1-year high of $32.76. The company has a current ratio of 2.44, a quick ratio of 2.44 and a debt-to-equity ratio of 0.01.

Phreesia (NYSE:PHR) last announced its earnings results on Monday, December 8th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.11. Phreesia had a negative net margin of 1.16% and a negative return on equity of 1.31%. The business had revenue of $120.33 million during the quarter, compared to the consensus estimate of $119.98 million. During the same quarter in the previous year, the firm posted ($0.25) EPS. Phreesia’s revenue was up 12.7% compared to the same quarter last year. Analysts expect that Phreesia, Inc. will post -1.1 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on PHR shares. Robert W. Baird dropped their price target on Phreesia from $31.00 to $25.00 and set an “outperform” rating for the company in a report on Wednesday, December 10th. DA Davidson lifted their price objective on shares of Phreesia from $33.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, December 2nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Phreesia in a research report on Friday, October 31st. JPMorgan Chase & Co. reduced their target price on Phreesia from $32.00 to $29.00 and set an “overweight” rating on the stock in a report on Tuesday, December 9th. Finally, Mizuho dropped their price target on Phreesia from $36.00 to $28.00 and set an “outperform” rating for the company in a research note on Wednesday, December 10th. Seventeen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.06.

Hedge Funds Weigh In On Phreesia

Institutional investors have recently modified their holdings of the business. Royal Bank of Canada boosted its stake in Phreesia by 208.8% in the first quarter. Royal Bank of Canada now owns 24,119 shares of the company’s stock valued at $617,000 after buying an additional 16,309 shares in the last quarter. AQR Capital Management LLC increased its position in Phreesia by 471.2% during the 1st quarter. AQR Capital Management LLC now owns 160,032 shares of the company’s stock worth $4,090,000 after purchasing an additional 132,015 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Phreesia by 3.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,557 shares of the company’s stock valued at $1,599,000 after purchasing an additional 2,158 shares during the last quarter. NewEdge Advisors LLC boosted its position in Phreesia by 262.7% in the first quarter. NewEdge Advisors LLC now owns 15,437 shares of the company’s stock valued at $395,000 after buying an additional 11,181 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in shares of Phreesia by 0.4% during the first quarter. Goldman Sachs Group Inc. now owns 600,012 shares of the company’s stock worth $15,336,000 after buying an additional 2,402 shares during the last quarter. Institutional investors and hedge funds own 92.10% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.